Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
- DOI
- 10.1007/s40120-023-00533-1
- Published
- 2023 Dec
- Container
- Neurology and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40120-023-00533-1,
title = {Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.},
author = {Aldred J and Freire-Alvarez E and Amelin AV and Antonini A and Bergmans B and Bergquist F and Bouchard M and Budur K and Carroll C and Chaudhuri KR and Criswell SR and Danielsen EH and Gandor F and Jia J and Kimber TE and Mochizuki H and Robieson WZ and Spiegel AM and Standaert DG and Talapala S and Facheris MF and Fung VSC},
year = {2023},
journal = {Neurology and therapy},
doi = {10.1007/s40120-023-00533-1},
url = {https://doi.org/10.1007/s40120-023-00533-1}
}RIS
TY - JOUR TI - Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. AU - Aldred J AU - Freire-Alvarez E AU - Amelin AV AU - Antonini A AU - Bergmans B AU - Bergquist F AU - Bouchard M AU - Budur K AU - Carroll C AU - Chaudhuri KR AU - Criswell SR AU - Danielsen EH AU - Gandor F AU - Jia J AU - Kimber TE AU - Mochizuki H AU - Robieson WZ AU - Spiegel AM AU - Standaert DG AU - Talapala S AU - Facheris MF AU - Fung VSC PY - 2023 JO - Neurology and therapy DO - 10.1007/s40120-023-00533-1 UR - https://doi.org/10.1007/s40120-023-00533-1 ER -
APA
J, A., E, F., AV, A., A, A., B, B., F, B., M, B., K, B., C, C., KR, C., SR, C., EH, D., F, G., J, J., TE, K., H, M., WZ, R., AM, S., DG, S., S, T., MF, F., & VSC, F. (2023). Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.. Neurology and therapy. https://doi.org/10.1007/s40120-023-00533-1
Source records
- pubmed · retrieved 2026-09-27T01:11:05.375Z